Microalbumin/Creatinine Ratio Test · Urine

Your kidneys are silent for a long time. They can lose a substantial amount of function before standard blood tests show anything wrong, and by the time creatinine creeps up, real damage has usually been done. The urine albumin-to-creatinine ratio catches that damage earlier, often by a decade, by spotting tiny amounts of a blood protein called albumin slipping through the kidney filter.

This number does more than track kidneys. Even values inside the standard "normal" range have been linked to higher risk of heart attack, stroke, high blood pressure, and earlier death. It is one of the few tests that gives you a window into how well your blood vessels and your kidneys are aging at the same time.

What This Test Actually Measures

ACR (albumin-to-creatinine ratio) is calculated from a single spot urine sample. The lab measures two things: albumin, a blood protein your liver makes that should almost never appear in urine, and creatinine, a steady waste product from muscle that flows into urine at a fairly constant rate. Dividing one by the other corrects for how concentrated or dilute your urine happens to be that day, so a single sample approximates a full 24-hour collection.

When albumin shows up in urine, it usually means your kidney filter (the glomerulus) has become slightly leaky. That leakiness reflects damage to the tiny blood vessels in the kidney, and because the same kind of vessels run through your heart, brain, and the rest of your body, ACR also serves as a signal of broader blood vessel health.

Heart Disease and Stroke Risk

The cardiovascular signal in this test is striking. In a study of 14,464 adults with high blood pressure, those with severe albuminuria had a significantly higher risk of major cardiovascular events, heart failure, and kidney disease than those without albuminuria. In a community-based prospective study of 3,627 adults in Beijing, even low-grade albuminuria predicted later cardiovascular events.

The risk does not start at the standard 30 mg/g threshold. In a Korean health-screening cohort of 39,091 adults with ACR below 30 mg/g, the highest quartile of "normal" (about 7.4 mg/g and up) was associated with nearly double the risk of developing high blood pressure and a higher risk of cardiovascular death compared to the lowest quartile. Among 23,697 U.S. adults, ACR within the normal range still predicted higher all-cause mortality, especially in people with poor cardiovascular health.

What this means for you: a number under 30 should not be read as "all clear." If your ACR is in the high single digits or low teens, that is a meaningful early signal, particularly if your blood pressure or cholesterol numbers are also borderline.

Type 2 Diabetes and Kidney Disease

In diabetes, ACR is the earliest reliable indicator that the kidneys are starting to feel the strain. In a study of 8,975 people with type 2 diabetes, rising ACR was an independent predictor of new heart and brain blood vessel disease, and adding it to existing risk models improved how well those models forecast events.

In a cohort of 4,821 people with type 2 diabetes, an ACR cutoff above 10 mg/g best predicted who would develop and progress through chronic kidney disease, well below the textbook 30 mg/g threshold. In prediabetes, a cutoff of 7.54 mg/g identified people at higher kidney disease risk in a study of 1,220 adults.

Mortality Across Many Populations

In a propensity score-matched study of 1,738 people with atherosclerotic cardiovascular disease, higher ACR was tied to higher long-term mortality independent of kidney filtration rate. In a national U.S. cohort tracked from 2003 to 2018, ACR within the normal range was independently linked to higher all-cause mortality among adults with diabetes who still had preserved kidney function.

Across general population studies, the risk curve is roughly log-linear: there is no clean safe threshold. Risk begins to climb around 5 to 10 mg/g and keeps rising from there.

Reference Ranges

These ranges come from major guideline bodies and large cohort studies in adult populations. ACR varies day to day, can be affected by sex and body composition, and is reported as mg of albumin per g of creatinine. Treat the cutoffs as orientation rather than absolutes, and always compare your results to your own prior values within the same lab.

Compare your results within the same lab over time for the most meaningful trend. Different labs may use slightly different methods that can shift the absolute number.

Tracking Your Trend

ACR is a noisy biomarker. The within-person coefficient of variation (a measure of how much a value bounces around in the same person) is roughly 30 to 49 percent across studies. In one analysis of people with type 2 diabetes, repeat values could range from about a quarter of the first reading to nearly four times higher, purely from biological variability. On consecutive days, an ACR change of about 170 percent is needed to be 95 percent confident that something real has shifted.

That noise is exactly why a single number can mislead. Guidelines suggest confirming an abnormal result with two of three samples spread over three to six months. For monitoring whether a treatment or lifestyle change is actually working, averaging two samples at each time point sharply improves your ability to detect a real shift.

A practical cadence: get a baseline now, retest in three to six months if you are making changes (medication, diet, blood pressure control), then at least annually. If you have diabetes, hypertension, or a family history of kidney disease, push toward annual testing as a minimum and more often if your number is moving.

Decision Pathway for an Abnormal Result

If your ACR comes back above 30 mg/g, do not panic, but do not ignore it either. The first move is to confirm with a repeat sample within a few weeks, ideally a first-morning urine, since intense exercise, dehydration, and acute illness can all push the number up transiently. If two of three samples over three to six months stay elevated, that pattern meets the criteria for kidney damage.

Pair this number with three companion tests: serum creatinine and cystatin C with eGFR (a calculation of how well your kidneys filter blood), a comprehensive lipid panel, and blood pressure. ACR plus eGFR together stratify cardiovascular and kidney risk far better than either alone. In one large analysis, adding eGFR and ACR to traditional risk factors meaningfully improved cardiovascular risk prediction, with the biggest gains for cardiovascular death and heart failure.

If ACR is persistently above 30 mg/g, especially with reduced eGFR, consider involving a nephrologist. If ACR is high and you have type 2 diabetes, the evidence-based response includes specific medications discussed in the interventions section. If ACR is in the "high-normal" range (roughly 7 to 30 mg/g), treat it as an early signal: tighten blood pressure, address insulin resistance, and retest sooner rather than later.

When Results Can Be Misleading

• Recent intense exercise: a single 40-minute high-intensity workout caused roughly a 16-fold rise in urinary albumin in elite athletes, with values returning to baseline by 48 hours. Avoid heavy training for 24 to 48 hours before collection.
• Body composition and obesity: people with high muscle mass excrete more creatinine, which can underestimate true albuminuria. In obese individuals, a 24-hour albumin collection may reveal albuminuria that ACR misses.
• Acute illness or dehydration: temporary spikes can occur during illness, fever, or significant dehydration; retest when you feel well and are hydrated normally.
• Day-to-day biological variability: a single reading carries a wide margin of error. Treat changes under 30 to 50 percent as noise unless confirmed on repeat testing.

Who This Number Matters Most For

If you have diabetes, high blood pressure, established cardiovascular disease, or a family history of kidney disease, ACR is one of the highest-yield tests you can run. In a primary care albuminuria screening study of 9,890 adults, adding ACR identified chronic kidney disease in people with otherwise normal eGFR and reclassified 36 percent of participants to higher risk, making more eligible for kidney-protective therapies. In home-based screening of the general population in the Netherlands, 62 percent of those with elevated ACR had newly diagnosed albuminuria, and most were referred for preventive treatment.

For everyone else, ACR is still worth knowing. The risk gradient starts well inside the "normal" range, and a baseline now gives you a starting point against which any future shift becomes meaningful.